|
Living Medical Textbook From Projects In Knowledge |
|
| Chapter 1 Parkinson's Disease: The Importance of Early Diagnosis Last Updated: June 15, 2010 |
||
| Chapter 2 Clinical Trial Design in Parkinson's Disease Release date: May 17, 2010 |
||
| Chapter 3 MAO-B Inhibitors in Parkinson's Disease: Evaluating the Evidence for Neuroprotection Release date: July 07, 2010 |
||
|
||
|
| Table of Contents |
|
Chapter 3 - MAO-B Inhibitors in Parkinson's Disease: Evaluating the Evidence for Neuroprotection |
|
Do monoamine oxidase type B (MAO-B) inhibitors modify the course of early Parkinson’s disease (PD)? Has the in vitro and preclinical evidence of neuroprotective activity for this class of drugs been borne out in clinical trials? These questions have been debated for at least 2 decades, and as yet, there is no clear consensus. Nonetheless, these remain important questions to consider because where you stand and how you interpret the data should affect how and when you use MAO-B inhibitors in the care of your PD patients. Find out more in the third chapter of this Living Medical Textbook, “MAO-B Inhibitors in Parkinson’s Disease: Evaluating the Evidence for Neuroprotection.”  top |
| |
|
Chapter 2 - Clinical Trial Design in Parkinson's Disease |
|
Bernard M. Ravina, MD, describes the two methods used in clinical trials to evaluate the neuroprotective properties of PD medications: neuroimaging as a biomarker of neuronal degeneration, and specialized clinical trial designs intended to differentiate neuroprotective effects from symptomatic effects. He also reviews their advantages and potential shortcomings, and offers some examples of how they have been used in trials of investigational drugs for PD. top |
| |
|
Chapter 1 - Parkinson's Disease: The Importance of Early Diagnosis |
|
Parkinson’s disease is traditionally diagnosed clinically based on classic motor symptoms of tremor, rigidity, bradykinesia, and postural instability. However, it is increasingly recognized that motor symptoms are only one manifestation of this chronic neurodegenerative disease—and a late manifestation at that. This chapter of the Parkinson's Disease Edition of the Living Medical Textbook describes the early symptoms of Parkinson’s disease, the underlying pathophysiology behind them, and available treatments for early Parkinson’s disease. Hyperlinks throughout the chapter lead the reader to more detailed and specific information on these topics from a variety of sources on the Internet in a multitude of formats. This first chapter sets the stage for a discussion of clinical trials and the neuroprotective potential of monoamine oxidase type B inhibitors in the management of early Parkinson’s disease. top |
| |
|
| CME INFORMATION |
ACTIVITY GOAL |
| The goal of this CME/CE activity is to examine preclinical nonmotor features, disease modification trials, clinical disease progression, MAO-B inhibitors, and current strategies for treating and managing patients with Parkinson's disease. |
TARGET AUDIENCE |
| This CME/CE activity is designed for Parkinson’s disease physician specialists, community neurologists, Parkinson’s disease nurse specialists, advanced practice healthcare professionals, managed care, and other allied health professionals. |
LEARNING OBJECTIVES |
|
| top1947 |
|
|||
|
This independent CME/CE activity is supported by an educational grant from
Teva Neuroscience. |
|||
| EDITORIAL BOARD | |||
| EDITOR-IN-CHIEF Robert A. Hauser, MD, MBA |
|||
|
|||
| CONTRIBUTING EDITOR Mark F. Lew, MD |
|||
|
|||
| CONTRIBUTING EDITOR Bernard M. Ravina, MD, MSCE |
|||
|
|||
